 This is an open label, single group, non-randomized, phase I study with cohort expansion that utilizes the standard 33 design for dose. The dose of selinexor will be escalated in combination with the standard doses of irinotecan. The maximum tolerated dose MTD for study is defined as the highest dose level at which 1 or less of 6 patients experience a dose limiting toxicity DLT. 